Christian Sherk

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 367 citations · Full text

Highly Potent Inhibitor, Tumor Biology, Mammalian Target +16

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

Christina Blackwell, Christian Sherk, Maggie Fricko et al. · Oncotarget · 2016 · 39 citations · Full text

Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors

Hong Lin, Mark J. Schulz, Ren Xie et al. · ACS Medicinal Chemistry Letters · 2012 · 38 citations · Full text

Combinatorial Chemistry, Chemoprevention Strategy, Pharmacotherapy +20

Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Andrew Fedoriw, Leilei Shi, Shane W. O’Brien et al. · Cancer Immunology Research · 2022 · 30 citations · Full text

Immunology, Immunologic Mechanism, Cd4 T Cell Responses +18